Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05431855
Other study ID # STUDY00002534
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2023
Est. completion date December 31, 2024

Study information

Verified date October 2023
Source Florida State University
Contact Yan Wang, PhD
Phone 352-294-5942
Email ywang48@ufl.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, participants will be asked to wear a wrist alcohol biosensor for 30 days and report alcohol use using a ecological momentary assessment (EMA) app. A subset of the sample will be micro-randomized to test two engagement strategies--reciprocity and personalized feedback via the eWrapper app to promote their engagement with the biosensor.


Description:

YPLWH (N = 160, 136 after 15% attrition, 18-29 years of age, estimated to include 73% male, 26% female, 1% transgender, 70% racial and ethnic minorities) will be asked to wear a wrist alcohol biosensor (BACtrack Skyn) for 30 days and report their alcohol use using daily ecological momentary assessment (EMA). A subset of the sample will also be micro-randomized twice daily to test two empirically-based engagement strategies - reciprocity and personalized feedback. Data from the 30-day MRT will be used to (a) develop and validate the algorithm for alcohol detection based on Skyn data; and (b) address scientific questions concerning which engagement strategy works best, for whom and under what conditions in terms of facilitating proximal engagement in biosensor wearing. We will also collect alcohol biomarker (i.e., PEth) at 1-month follow up.


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 29 Years
Eligibility Inclusion Criteria: - 18 years and 0 months to 29 years and 11 months - Currently reside in Florida - Report having had at least 1 alcoholic drink in the last 30 days - Able to read and understand English - Have internet access via smartphone, tablet or computer - Be diagnosed as HIV positive and; - Willing to provide informed consent. Exclusion Criteria: - Adults unable to consent - Individuals who are not yet adults - Individuals who are not diagnosed as HIV+ - Prisoners - Pregnant women

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
eWrapper-Engagement strategies to facilitate alcohol biosensor wearing
We will conduct a 30-day micro-randomized trial (MRT)--a clinical trial design for developing and optimizing mHealth interventions to test which engagement strategy works better, for who, and under what condition. A subset of the participants will be micro-randomized in the morning and in the evening, to either a prompt delivering non-contingent small reward (reciprocity); or a prompt containing feedback on self-monitoring progress based on dynamic self-regulation theories (personalized feedback); or no prompt.

Locations

Country Name City State
United States The University of Michigan Ann Arbor Michigan
United States The University of Florida Gainesville Florida
United States Florida State University Tallahassee Florida

Sponsors (3)

Lead Sponsor Collaborator
Florida State University University of Florida, University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Engagement in biosensor wearing For the whole sample, it is an observational study, so the outcome is just percentage of biosensor wearing during the 30 day period.
For the subset who also go through MRT for engagement strategies, we will test the effect of each strategy using % time wearing the sensor in the next 12 hours as the proximal outcome. We hypothesize that the engagement strategies will be better than no prompt and that reciprocity will have an advantage over personalized feedback as it requires less cognitive processing.
Within 12 hours after prompted engagement strategy
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2